20 May 2013
Keywords: idec, arthritis, drug, enters, phase, iii, pharmaceuticals
Article | 23 December 1996
IDEC Pharmaceuticals has reported that partner SmithKline Beecham has
started a Phase III trial of IDEC-CE9.1 (also known as SB210396), ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
There are no related articles.
17 May 2013
© 2013 thepharmaletter.com